Brokerages Set Tilray Brands, Inc. (NASDAQ:TLRY) PT at $15.00

Tilray Brands, Inc. (NASDAQ:TLRY) has been assigned an average rating of “Reduce” from the seven analysts that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and one has given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $13.3333.

A number of research firms have recently commented on TLRY. Zacks Research downgraded shares of Tilray Brands from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 13th. Roth Mkm dropped their target price on Tilray Brands from $20.00 to $10.00 and set a “neutral” rating on the stock in a report on Tuesday. Atb Cap Markets raised Tilray Brands from a “strong sell” rating to a “hold” rating in a research report on Wednesday, December 10th. Wall Street Zen upgraded Tilray Brands from a “strong sell” rating to a “hold” rating in a research note on Saturday, October 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tilray Brands in a research report on Wednesday, October 8th.

Key Headlines Impacting Tilray Brands

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Tilray announced the launch of Tilray Medical Italia, rebranding its Italian operations and expanding a EU?GMP medical cannabis portfolio via a partnership with Molteni Farmaceutici — a strategic move that strengthens Tilray’s presence in a regulated European market and could help steady medical?cannabis revenue. Tilray Medical Strengthens Italian Market Presence with the Launch of Tilray Medical Italia and Expanded Medical Cannabis Portfolio
• Positive Sentiment: SweetWater Brewing (a Tilray brand) launched Big Trip Double IPASweetWater Introduces Big Trip Double IPA: A Bold New Craft Beer
• Positive Sentiment: Insider buying activity has been reported over the past six months (including purchases by the CEO and CFO), which investors often view as a bullish signal about management’s view of the company. Tilray Medical Launches Tilray Medical Italia, Expanding Presence in Italy’s Medical Cannabis Market
• Neutral Sentiment: Tilray reported record Q2 revenue ($217.5M), showing top?line momentum in cannabis, but the report highlighted mixed results with beverage segment underperformance — a signal that revenue growth exists but profitability and segment mix remain key risks. Tilray Brands Just Posted Record Numbers for Q2. Is the Stock a Buy?
• Neutral Sentiment: Analyst price targets are highly dispersed (median ~$6; recent targets range from $2 to $10), reflecting uncertainty and mixed views that can amplify volatility as new data arrive. Tilray Medical Launches Tilray Medical Italia, Expanding Presence in Italy’s Medical Cannabis Market
• Negative Sentiment: Roth MKM and at least one other analyst recently lowered expectations, triggering a sell reaction (coverage noted shares falling ~7.4% in response) — a near?term headwind that can pressure the stock until fundamentals or guidance improve. Tilray Brands (NASDAQ:TLRY) Shares Down 7.4% on Analyst Downgrade

Institutional Trading of Tilray Brands

Several institutional investors and hedge funds have recently added to or reduced their stakes in TLRY. Oppenheimer & Co. Inc. bought a new position in shares of Tilray Brands in the 3rd quarter valued at about $25,000. Silverlake Wealth Management LLC acquired a new stake in Tilray Brands in the 3rd quarter valued at about $25,000. Unified Investment Management acquired a new stake in Tilray Brands in the 3rd quarter valued at about $26,000. Y Intercept Hong Kong Ltd bought a new position in Tilray Brands during the third quarter worth about $30,000. Finally, HighPoint Advisor Group LLC acquired a new position in Tilray Brands during the third quarter worth approximately $33,000. 9.35% of the stock is owned by institutional investors.

Tilray Brands Price Performance

Shares of TLRY opened at $9.13 on Tuesday. The company has a quick ratio of 1.72, a current ratio of 2.81 and a debt-to-equity ratio of 0.19. Tilray Brands has a twelve month low of $3.51 and a twelve month high of $23.20. The stock has a market capitalization of $1.06 billion, a P/E ratio of -0.41 and a beta of 1.77. The company has a 50 day moving average of $9.53 and a 200-day moving average of $10.84.

Tilray Brands (NASDAQ:TLRY) last announced its quarterly earnings data on Thursday, January 8th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.27). The business had revenue of $217.51 million during the quarter, compared to the consensus estimate of $211.15 million. Tilray Brands had a negative return on equity of 6.35% and a negative net margin of 251.69%.During the same period in the prior year, the firm earned ($0.03) EPS. As a group, equities research analysts forecast that Tilray Brands will post -0.2 EPS for the current fiscal year.

Tilray Brands Company Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.

Featured Stories

• Five stocks we like better than Tilray Brands
• Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
• How a Family Trust May Be Able To Help Preserve Your Wealth
• Do not delete, read immediately
• NEW LAW: Congress Approves Setup For Digital Dollar?
• Executive Order 14330: Trump’s Biggest Yet